New oral cancer drug enters human testing for advanced solid tumors
NCT ID NCT04905914
Summary
This early-stage study is testing a new oral medication called ATRN-119 in patients with advanced solid tumors that have specific genetic mutations. The main goals are to check the drug's safety, how it moves through the body, and see if it shows any early signs of effectiveness against cancer. The study involves 132 participants who have tried other treatments and have tumors that can be measured.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
NEXT Oncology- San Antonio
San Antonio, Texas, 78229, United States
-
NEXT Oncology- Virginia
Fairfax, Virginia, 22031, United States
-
NEXT- Oncology Dallas
Irving, Texas, 75039, United States
-
University Hospitals, Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
Yale Cancer Center
New Haven, Connecticut, 06520-8028, United States
Conditions
Explore the condition pages connected to this study.